The story begins with the biology of muscle repair itself. Skeletal muscle has a remarkable capacity to regenerate, and the workhorses of this process are muscle stem cells, known as MuSCs, which sit quietly beside muscle fibers until injury wakes them. Once activated, they proliferate, differentiate into myoblasts, and fuse to replace damaged tissue. But the stem cells do not act alone. They are embedded in a niche populated by immune cells, and the quality of repair depends on a precisely choreographed conversation between the two. Neutrophils flood the wound first, followed by pro-inflammatory macrophages that clear dead debris and release signals such as interleukin-6 and prostaglandin E2, which push MuSCs into their activation and expansion phase.

In a young, healthy muscle, this fiery opening act gives way to a calmer second act. Macrophages shift toward an anti-inflammatory profile, and the tissue begins producing a family of bioactive fats called specialized pro-resolving mediators, or SPMs. These molecules, which include resolvins, protectins, and maresins and are derived mainly from omega-3 polyunsaturated fatty acids, do not simply suppress inflammation the way a steroid might. Instead, they actively drive the resolution program: they help clear neutrophils, encourage macrophages to adopt repair-oriented states, and preserve the host defenses needed to fight infection. Crucially, this lipid-mediated class switch is what allows the regenerative environment to mature so that myoblasts can differentiate, fuse, and complete the repair.

Aging scrambles this choreography. Previous work has shown that old skeletal muscle is deficient in endogenous SPMs while remaining awash in pro-inflammatory eicosanoids such as prostaglandins and leukotrienes. The result is a niche stuck in first gear: macrophages and neutrophils linger far longer than they should, chronic inflammatory signaling persists, fibrosis accumulates, and MuSCs receive contradictory instructions that blunt their regenerative output. The Ottawa team, led by senior author Junio Dort, wanted to know whether supplying one key SPM from outside could compensate for this age-related deficit. They chose RvE1, the principal member of the E-series resolvins, which is derived from eicosapentaenoic acid and had been well characterized in other tissues but largely unexplored in skeletal muscle, where its D-series cousins had received most of the attention.

The first experiments were conducted in a dish. The researchers isolated bone marrow monocytes from mice older than twenty months, which corresponds to advanced age in the mouse lifespan, and differentiated them into macrophages. When these aged macrophages were stimulated with bacterial lipopolysaccharide and interferon-gamma to mimic an inflammatory assault, treatment with 200 nanomolar RvE1 produced a clear shift. The proportion of macrophages expressing CD206, a canonical anti-inflammatory marker, rose by roughly one and a half fold, while the fraction expressing CD163, another resolution-associated receptor, increased fourfold. Western blotting confirmed elevated CD206 protein. At the same time, quantitative PCR revealed that RvE1 significantly suppressed the expression of pro-inflammatory genes including tumor necrosis factor-alpha and transforming growth factor-beta, with downward trends in the neutrophil-recruiting chemokine CXCL1 and the inflammatory enzyme Ptgs2.

Interestingly, the molecule’s effects on classical anti-inflammatory genes such as interleukin-10 were modest. The authors interpret this selectivity through the lens of receptor biology. RvE1 signals primarily through ChemR23, a receptor enriched on inflammatory neutrophils and macrophages, where its activation dampens NF-kappaB signaling and cytokine production. In other words, RvE1 does not install a brand-new anti-inflammatory program; it switches off the persistent pro-inflammatory hum, and that silencing itself feeds back to promote pro-resolving macrophage polarization. This distinction matters therapeutically, because it suggests the molecule fine-tunes rather than blanket-suppresses immunity, preserving the early inflammatory cues that muscle stem cells actually need to begin repairing tissue.

The in vivo experiments then tested whether these cellular effects translate into better healing. The team injured the tibialis anterior muscle of aged mice with cardiotoxin and, beginning twenty-four hours after injury, gave the animals twice-weekly subcutaneous injections of RvE1 at five micrograms per kilogram for two weeks. Fourteen days later, the treated muscles looked meaningfully different from the vehicle controls. Total macrophage infiltration trended downward, the proportion of anti-inflammatory F4/80-positive CD206-positive macrophages rose significantly, and neutrophil accumulation, measured by Ly6G staining, dropped markedly. The regenerating tissue also contained more PAX7-positive muscle stem cells and more MYOG-positive differentiating myoblasts, indicating an expanded and more advanced myogenic cell pool.

Some structural measures told a subtler story. RvE1 did not change the number of newly formed embryonic myosin heavy chain-positive fibers or the average fiber cross-sectional area at the day-14 endpoint, but it significantly reduced the percentage of centrally nucleated fibers, a hallmark of repeated cycles of degeneration and regeneration, and showed a downward trend in collagen-rich fibrotic areas. Force testing with a dual-mode lever system revealed a general trend toward improved contractile function in the treated muscles, although the authors are careful to note that the relatively small sample size of three animals per group limited statistical power for some histological and functional outcomes. The picture that emerges is one of accelerated regenerative kinetics rather than a finished product: RvE1 appears to move the whole repair process forward in time.

The team also asked whether RvE1 acts directly on the muscle stem cells themselves, not just on their immune environment. When primary myoblasts isolated from aged mice were treated with RvE1 for sixteen hours in proliferation medium, levels of the myogenic transcription factor MYOD rose significantly, accompanied by increased Ki67 staining, a marker of active cell division. After four days in differentiation conditions, however, the molecule had minimal effect on myotube diameter or fusion index, suggesting that its direct myogenic action is concentrated in the early expansion phase. The authors propose that RvE1 may engage the BLT1 receptor expressed on myoblasts, and that in living muscle, RvE1-polarized anti-inflammatory macrophages likely add a paracrine boost by secreting myogenic growth factors such as insulin-like growth factor-1 and interleukin-4.

The study has limitations the authors acknowledge candidly. Macrophage polarization was assessed mainly through CD206 and CD163, whereas macrophage activation is now understood as a continuum of states rather than a binary M1/M2 switch; single-cell transcriptomics would paint a richer picture. The single day-14 endpoint cannot capture whether early cellular gains mature into lasting architectural and functional improvements, and the trends in fibrosis and muscle force await confirmation in larger cohorts. Native RvE1 is also hampered by a short biological half-life, though metabolically stable analogs and orally active SPM mimetics are in development, and early clinical studies of SPM-enriched supplements have shown encouraging effects on inflammatory biomarkers in conditions such as knee osteoarthritis. Even with those caveats, the convergence of evidence is compelling: a single omega-3-derived lipid can reprogram the aged muscle niche, clearing out lingering neutrophils, steering macrophages toward repair, expanding the stem cell pool, and nudging old muscle toward the regenerative behavior of its younger self. For a population whose falls, frailty, and lost independence trace back to muscles that no longer heal, that is a molecule worth watching.

Subject of Research: The role of the specialized pro-resolving mediator Resolvin E1 in inflammation resolution and skeletal muscle regeneration during aging

Article Title: Resolvin E1 promotes the resolution of inflammation and enhances myogenic responses during aged skeletal muscle regeneration

Article References: Arsenault, R., Ziadeh, A., Assebbane, A., Yezihalem, H., Green, A., & Dort, J. (2026). Resolvin E1 promotes the resolution of inflammation and enhances myogenic responses during aged skeletal muscle regeneration. GeroScience. https://doi.org/10.1007/s11357-026-02566-4

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02566-4

Keywords: Resolvin E1, specialized pro-resolving mediators, skeletal muscle regeneration, muscle stem cells, macrophage polarization, inflammation resolution, aging, omega-3 fatty acids, myogenesis, neutrophil clearance, fibrosis, GeroScience

For decades, muscle aging was attributed mainly to intrinsic defects within myofibers or to the exhaustion of muscle stem cells, known as MuSCs. The review, drawing on recent single-cell RNA sequencing, spatial transcriptomics, multimodal atlases, and lineage-tracing studies, contends that these explanations are incomplete. Instead, aging reshapes the entire cellular ecosystem: stem cells lose regenerative competence, fibro-adipogenic progenitors become locked into pro-fibrotic states, immune populations fail to resolve inflammation, vascular support declines, and neuromuscular junctions undergo incomplete reinnervation. No single defect explains the decline; rather, it is the desynchronization of the whole system that drives tissue deterioration.

The fate of muscle stem cells illustrates this population-level remodeling. In geriatric mice aged twenty months or older, a fraction of MuSCs loses the capacity for reversible quiescence and drifts into a pre-senescent state, impairing later activation, proliferation, and self-renewal. Time-resolved trajectory analyses show that aged stem cells broadly preserve the overall sequence of activation and differentiation, but their responses are delayed and progress with highly heterogeneous kinetics. Epigenetic instability contributes to this decline: age-associated depletion of S-adenosylmethionine, a critical methyl donor, weakens repressive histone methylation and heterochromatin architecture, promoting DNA damage and apoptosis. Restoring intracellular SAM levels in experiments re-established heterochromatin domains and mitigated age-related regenerative defects.

One of the most provocative concepts in the review is what the authors call cellular survivorship bias. In aged stem cells, elevated expression of the tumor suppressor NDRG1 strongly suppresses mTOR signaling, a principal pathway governing cellular activation and expansion. This appears to function as a cellular brake that prioritizes long-term survival under chronic inflammatory and oxidative stress at the expense of rapid tissue repair. Pharmacologically inhibiting NDRG1 temporarily restores youthful activation and accelerates early repair, but repeated injury cycles lead to severe cellular stress and depletion of the remaining stem cell pool. The surviving cells in aged muscle, in other words, are not optimized for regeneration but selected for persistence under hostile conditions.

Immune dynamics add a second layer of dysfunction. After injury, platelets release chemokines such as CXCL4 and CXCL5 that recruit neutrophils and monocytes, which are later superseded by macrophages clearing debris and supporting myogenesis. In aged muscle, this choreography falters. Inflammatory and senescence-related immune programs persist beyond the window of productive repair, and specific aged M2-like macrophage subsets sustain secretion of pro-fibrotic factors including TGF-beta and osteopontin, driving neighboring stromal cells to deposit excess collagen. Meanwhile, the local accumulation of regulatory T cells, which normally dampen inflammation and supply pro-resolving signals such as IL-10, is markedly reduced or delayed. The result is a temporal mismatch: stem cells need an anti-inflammatory environment to build new fibers, yet the aged niche remains saturated with early inflammatory signals.

Fibro-adipogenic progenitors, or FAPs, are central players in this degenerative relay. In young tissue they transiently expand after injury, secrete extracellular matrix components that support myogenic progenitors, and then either self-eliminate or return to quiescence. Aging destroys this plasticity. Single-cell and spatial analyses reveal that aged FAPs diverge into aberrant states marked by osteopontin, Sca1, Dpp4, or, in human atlases, CD90 expression, all associated with chronic inflammation and fibrosis. Crucially, not all FAPs fail; subpopulations with anti-inflammatory, pro-regenerative signatures persist. The pathology is therefore not wholesale corruption of the stromal compartment but a loss of temporal plasticity, the inability to exit fibrotic states once repair is complete, leading to fibro-adipose remodeling that progressively replaces muscle with scar and fat.

The communication breakdown between stem cells and stromal cells is particularly well documented. FAP-derived WISP1 activates AKT signaling in MuSCs to promote productive proliferation, while fibronectin in the niche regulates adhesion and polarity through integrin-FAK signaling. Both supports decline with age. At the same time, epigenetically perturbed aged stem cells secrete IL-6, osteopontin, and CCN2, factors that push adjacent FAPs toward excessive expansion and collagen production. Senescent stem cells thus act not as passive casualties but as active instigators, propagating their defects through paracrine signaling. Genetic knockdown of CCN2 in aged MuSCs improves regenerative outcomes and attenuates fibrosis, while forced overexpression compromises engraftment and stimulates fibroblast expansion.

Senescence amplifies the damage through additional channels. Senescent FAPs secrete CCL2 and osteopontin, which entrap macrophages in a pro-inflammatory state and sustain a self-reinforcing macrophage-FAP feedback loop. In progeroid and dystrophic mouse models, eliminating senescent cells with the senolytic compound fisetin restores the stem cell pool and regenerative efficacy. Stress-induced senescent myoblasts release extracellular vesicles carrying senescence-associated cargo that induces secondary senescence in endothelial cells, compromising the vasculature repair depends on. Another senescent-cell product, the lipid 15d-PGJ2, covalently modifies the HRas protein in healthy neighboring myoblasts, hyperactivating ERK signaling and blocking myogenic differentiation. These findings show that the senescence-associated secretory phenotype extends well beyond soluble cytokines to transferable, non-protein signals.

The neuromuscular junction constitutes a specialized microdomain where these failures converge. Synaptic destabilization and motor unit remodeling often precede measurable sarcopenia, producing a mosaic of denervated, reinnervated, and unstable myofibers. Terminal Schwann cells guide regenerating axons back to motor endplates, and their ablation in adult mice severely impairs reinnervation and force recovery. Mesenchymal progenitors near motor axons supply trophic support, most notably the protein BMP3B, whose expression declines with age in both mice and humans; sustained expression in aged mice attenuates neuromuscular degeneration, muscle atrophy, and functional decline. Intriguingly, osteopontin displays context-dependent duality: it drives chronic fibrosis in the broader stroma yet acts as an indispensable neurotrophic factor at the synapse, a caution against blunt therapeutic targeting.

The review closes with a sober assessment of what remains unknown. Most ligand-receptor interactions proposed by computational analyses of omic data are still correlative, and only a limited set of signaling pathways, including WISP1 supplementation, CD47 blockade, and senescent FAP clearance, have been functionally validated in vivo. A further challenge is the translational gap between acute, synchronized murine injury models and the chronic, insidious muscle attrition characteristic of human sarcopenia. The authors argue that effective rejuvenation strategies must abandon single-cell targets in favor of restoring the entire multicellular network: stem-stromal crosstalk, immune resolution, vascular support, and neuromuscular communication. Treating aging muscle as an interconnected system, they conclude, offers the most realistic path toward dismantling degenerative loops and preserving strength in old age.

Subject of Research: Multicellular crosstalk and population dynamics in skeletal muscle aging and sarcopenia

Article Title: From Regenerative to Degenerative Niche: Multicellular Crosstalk and Population Dynamics in Skeletal Muscle Aging

Article References: Kim, S., Kim, M. J., & Yang, Y. R. (2026). From Regenerative to Degenerative Niche: Multicellular Crosstalk and Population Dynamics in Skeletal Muscle Aging. Aging Cell, 25(10), Article e70733. https://doi.org/10.1111/acel.70733

Image Credits: AI Generated

DOI: 10.1111/acel.70733

Keywords: skeletal muscle aging, sarcopenia, muscle stem cells, fibro-adipogenic progenitors, single-cell RNA sequencing, spatial transcriptomics, cellular senescence, macrophages, fibrosis, neuromuscular junction, intercellular communication, regeneration

The case for MuSCs rests on their intrinsic commitment to the myogenic lineage. Unlike pluripotent stem cells, which require elaborate and tightly controlled differentiation protocols before they reliably become muscle, or mesenchymal stromal cells, which convert into muscle fibers only with variable and often disappointing efficiency, MuSCs are already wired for the job. In living animals they are responsible for growth, repair, and regeneration of skeletal muscle, and when activated by environmental cues they proliferate, differentiate, and fuse into the multinucleated myofibers that give meat its characteristic texture. That lineage fidelity translates into straightforward induction conditions in the laboratory and a direct biological relevance to the tissue being reconstructed. Because MuSCs can be harvested directly from livestock skeletal muscle, the resulting cultured product begins its life with the same cellular identity as conventional meat, which is precisely what regulators and consumers will scrutinize.

The catch is that MuSCs, like other primary cells, are mortal in culture. During extended in vitro passage they undergo phenotypic drift and eventually replicative senescence, progressively losing both proliferative capacity and myogenic potential. For a commercial process that may require many population doublings to accumulate enough biomass, this finite lifespan is a fundamental constraint. The review emphasizes that performance also varies with species, breed, donor age and sex, and even the anatomical origin of the muscle from which the cells are isolated. One cited study found that MuSCs from Hanwoo steers proliferated faster and doubled more quickly than cells from Hanwoo cows, with distinct marker expression profiles and differentiation kinetics. The authors call for standardized reporting of population doubling time, proliferation rate, differentiation kinetics, and fusion efficiency so that results from different laboratories can be meaningfully compared and robust cell lines identified.

Understanding myogenesis at the molecular level is the second pillar of the roadmap. Myogenic regulatory factors, including MYF5, MYOD, myogenin, and MRF4, orchestrate the progression from quiescent stem cell to fused myotube, and their expression serves as the standard molecular readout of myogenic status. Growth factors modulate every step of this cascade: IGF-1 drives growth and protein synthesis, FGF-2 sustains the proliferation of bovine and porcine MuSCs while delaying premature differentiation, PDGF promotes myoblast expansion, HGF wakes quiescent cells, and TGF-beta participates in repair and matrix remodeling but can suppress myogenesis depending on context. Beyond the classic factors, immune-derived cytokines exert surprisingly powerful effects. Interleukin-6 significantly enhanced bovine satellite cell proliferation in serum-free media in one study, interleukin-15 promotes myosin heavy chain accumulation, and interleukin-4 drives the secondary fusion step that builds mature myofibers. Myokines such as decorin, which sequesters the muscle-growth inhibitor myostatin in the extracellular matrix, and irisin add further layers of regulation.

Myostatin itself emerges as one of the most promising molecular levers. A member of the TGF-beta superfamily, myostatin is a potent negative regulator of muscle growth, and its genetic disruption in mice and double-muscled cattle produces dramatic increases in muscle mass. In culture, inhibiting myostatin or its downstream SMAD2/3 signaling enhances MuSC differentiation, promotes myotube formation, and upregulates key myogenic markers. Notably, computational docking screens of natural product databases have identified food-relevant plant compounds, including licochalcone A and B, quercetin, and laxogenin, as candidate myostatin inhibitors, and subsequent experimental work showed that these compounds can enhance MuSC proliferation and differentiation or protect cells from oxidative stress. The review is careful to note that such in silico hits are hypothesis generators, not proven ingredients, and that most evidence still comes from rodent or cell-line models rather than primary livestock cells.

That caveat points to the field’s most stubborn bottleneck: the culture medium. Standard formulations rely on fetal bovine serum, an animal-derived cocktail that is expensive, compositionally variable from batch to batch, ethically fraught, and incompatible with a food product meant to reduce reliance on livestock. Serum-free and chemically defined media exist, and formulations such as Beefy-9 have supported sustained expansion of bovine satellite cells across multiple passages while preserving myogenicity, but optimal compositions are highly species- and stage-specific. Media must also be modulated across the process, with expansion formulations maintaining progenitor states and differentiation formulations triggering myotube formation. Economic analyses cited in the review estimate that culture media, particularly the recombinant growth factors used in serum-free systems, can account for roughly half or more of variable operating costs, making media design the decisive battleground for affordability.

This is where artificial intelligence enters the story. The review highlights Bayesian optimization approaches that have streamlined serum-free medium development for myoblasts, multi-objective AI designs that produced low-serum media with reduced cost and environmental impact, and machine learning frameworks that predict the quality and senescence state of porcine and Hanwoo muscle satellite cells from microscopy images alone. Computational screening of vast natural product libraries such as COCONUT, LOTUS, and ZINC can prioritize candidate bioactive compounds, growth factor substitutes, and even antibiotic alternatives before a single wet-lab experiment is run. The authors stress, however, that docking scores and predictions demand rigorous experimental validation of solubility, cytotoxicity, and effective concentrations in food-relevant cells, and that AI should be treated as a complement to, not a replacement for, experimental optimization.

Even with perfect cells and perfect media, meat is a three-dimensional structure, and recreating it is an engineering problem. Skeletal muscle is organized into hierarchical bundles of aligned myofibers wrapped in endomysium, perimysium, and epimysium, and its texture depends on fiber density, alignment, and the extracellular matrix proteins, chiefly collagens, laminins, and fibronectin, that scaffold the whole assembly. Scaffold research is shifting from generic tissue-engineering materials toward edible, food-grade options: soy protein porous scaffolds, whey protein isolate composites, zein-coated alginate fibers that align muscle cells, and decellularized mushroom-derived matrices that produced steak-like constructs with authentic texture. At production scale, anchorage-dependent MuSCs are grown on microcarriers in stirred-tank bioreactors, where recent work has demonstrated bovine satellite cell expansion at microcarrier concentrations up to 80 square centimeters per milliliter and transfer to 3-liter vessels, while edible soy protein microcarriers enabled a 24-fold expansion of bovine myoblasts in eight days followed by differentiation without any cell detachment step.

Safety, regulation, and environmental accounting complete the picture. Hazards span microbial contamination, residual antibiotics and reagents, genetic and phenotypic drift during prolonged culture, and the composition of any scaffold that remains in the final product, and the review argues for risk-based frameworks built on HACCP principles and good manufacturing practice rather than blanket rules. Regulatory pathways are already diverging, with Singapore treating cultured meat as a novel food requiring pre-market safety assessment while the US FDA and USDA share oversight. Life cycle assessments, meanwhile, show that environmental performance is exquisitely sensitive to energy sources, media purification, and production scale, meaning that generalized claims about cultured meat’s footprint should be treated with caution. The authors’ bottom line is that cultured meat will succeed only through integration: stable, well-characterized MuSC sources; defined, food-grade, affordable media; scalable bioprocesses; engineered tissue architecture; and AI-guided optimization, all tracked with quantitative benchmarks of productivity, differentiation efficiency, cost, and safety. The cells are willing. The challenge now is industrial.

Subject of Research: Muscle stem cell cultivation strategies and technical barriers for scalable cultured meat production

Article Title: MuSC cultivation for cultured meat production: recent advances, current limitations, and future directions

Article References: MuSC cultivation for cultured meat production: recent advances, current limitations, and future directions. (n.d.). https://doi.org/10.1007/s44463-026-00108-2

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00108-2

Keywords: cultured meat, muscle stem cells, myogenesis, serum-free media, myostatin, scaffolds, bioreactors, microcarriers, artificial intelligence, food safety, life cycle assessment, bioprocess engineering

The central insight of the review is a distinction between deficits within a phase and deficits at the transitions between phases. Aged skeletal muscle is impaired at every stage of post-injury repair that researchers have examined: immune cell recruitment is delayed and skewed in composition, the degradation of damaged debris lags behind its uptake, and muscle stem cells follow a broadly conserved activation trajectory but on delayed kinetics. Yet these within-phase problems may be differences of degree that a longer repair window can absorb. Transitions between phases offer no such slack. Each transition is triggered by a defined molecular switch, and if a compartment arrives late, it encounters a microenvironment already committed to a self-maintaining alternative state that its later output may be unable to reverse.

Three such switches anchor the repair sequence. The first is the fall in damage-related input that follows complete degradation of necrotic debris, which permits inflammation to begin resolving. The second is the balance between the inflammatory signal TNF and the profibrotic signal TGF-beta, which determines whether fibro-adipogenic progenitors, the stromal cells that temporarily support regeneration, undergo apoptosis and are cleared once their support phase ends. The third is the conversion of inflammatory Ly6C-high monocytes into reparative Ly6C-low macrophages, the immune pivot on which the shift from destruction to reconstruction depends. Because positive feedback loops operate beyond each of these switches, a lagging compartment does not simply slow the program; it can meet a tissue state that actively resists correction.

The review singles out retained mitochondrial lesions in postmitotic myofibers as one proposed input that can hold the first switch open. Skeletal muscle fibers are long-lived and cannot divide, so damaged mitochondrial DNA deletion mutations accumulate within individual fibers over decades, sometimes reaching detrimental levels intracellularly. These lesions can release mitochondrial DNA into the cytosol, where it activates the cGAS-STING innate immune pathway, a circuit that normally detects microbial DNA but misfires on self DNA. Mitophagy, the cellular quality-control system that normally removes damaged mitochondria, curtails this inflammatory activation in youth, but its capacity declines with age. The result is a persistent damage signal that keeps the injury phase of repair nominally alive even after the original wound has been cleared.

Meanwhile, the muscle stem cells themselves, the satellite cells that are absolutely required for regeneration, face a compounding set of problems. Their pool contracts with age, their fate allocation becomes skewed away from self-renewal, and they acquire cell-autonomous defects, including p38 MAPK-driven loss of self-renewal and p16- and p21-associated senescence, that persist even when aged cells are transplanted into a young host environment. Age-associated epigenetic changes can suppress genes such as SPRY1, causing stem cells to fail to return to quiescence and depleting the reserve pool needed for future injuries. The aged niche compounds this, with loss of fibronectin and WISP1 from fibro-adipogenic progenitors and stiffening of the extracellular matrix further degrading stem cell support.

The stromal compartment tells an equally troubling story. Fibro-adipogenic progenitors are essential early: they facilitate myogenesis, secrete supportive matrix proteins, and in youth are duly removed by TNF-triggered apoptosis once their job is done. In aged muscle, they resist clearance past their useful window, while the matrix around them stiffens and keeps pushing them toward a fibrogenic identity. Mechanotransduction studies show that substrate stiffness alone can drive progenitors into myofibroblasts, creating a feed-forward loop in which fibrosis begets more fibrosis. The same mechanical logic has been implicated in idiopathic pulmonary fibrosis, and the review argues that aged muscle may trap itself in an analogous self-reinforcing state from which no single late intervention can easily extract it.

The immune system completes the picture of desynchronization. Aged myeloid cells reach the pro-repair switch late and with attenuated output. Recruitment of inflammatory monocytes is delayed, their conversion to Ly6C-low reparative macrophages is blunted, and debris degradation lags behind phagocytic uptake, meaning material is swallowed but not fully digested. Regulatory T cells, which accumulate in injured muscle and potentiate repair through interleukin-33-dependent mechanisms, fail to accumulate properly in aged animals. The consequence is that when reparative macrophages and stem cells finally engage, the microenvironment has often already tipped toward chronic inflammation and matrix deposition, states maintained by their own positive feedback.

Crucially, the authors argue that none of these individual lesions need be the primary cause for the sequence to fail. This reframing has practical consequences for how regenerative interventions in aging should be judged. Rather than asking whether a therapy rescues one cell type in isolation, the review proposes evaluation against system-level criteria: does inflammation decline, does matrix remodeling close, does myogenic output yield mature fibers, and does the reserve stem cell pool survive repeated injury? Interventions that look promising in single-cell assays but leave transition timing intact failure would be expected to underperform, whereas approaches that restore coordination, even partially, may yield disproportionate benefit.

The framing also connects to a broader view of aging itself. Rather than a simple accumulation of damage in individual cells, aging here emerges as a systems-level breakdown in when things happen, not merely whether they happen. Sub-threshold delays, each individually tolerable, accumulate between compartments that must act in precise sequence, until one failed transition settles the tissue into an inflammatory-fibrotic endpoint that behaves like an alternative stable state. If this view is correct, future therapies for sarcopenia and poor healing in the elderly may need to target timing itself, restoring the ordered handoffs between macrophages, fibro-adipogenic progenitors, and stem cells, rather than simply boosting any one of them. The review, published as Volume 27, article 154 of Biogerontology, offers a conceptual scaffold for that next generation of studies.

Subject of Research: Temporal coordination failure, or phase-transition failure, in regeneration of aged skeletal muscle

Article Title: Phase-transition failure in aged skeletal muscle regeneration

Article References: Zhang, B., Shi, H., Guo, X., & Wang, Y. (2026). Phase-transition failure in aged skeletal muscle regeneration. Biogerontology, 27(5), Article 154. https://doi.org/10.1007/s10522-026-10500-6

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10500-6

Keywords: skeletal muscle, aging, regeneration, muscle stem cells, satellite cells, macrophages, fibro-adipogenic progenitors, inflammation, fibrosis, mitochondrial DNA, cGAS-STING, sarcopenia